Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)

Exclusion Criteria

• •Patients must not have radiographic or clinic disease progression while on induction therapy and/or prior to start of study treatment.
• •Patients must have received 4 cycles (21-day cycles) of induction with carboplatin or cisplatin, etoposide and durvalumab completed within 1 to 14 days prior to initiation of study treatment on C5D1. Patients must have received durvalumab at minimum three times during the four induction cycles.
• •Adequate organ and marrow function
• •Induction therapy other than carboplatin/cisplatin, etoposide and durvalumab. (The administration of one induction cycle without durvalumab is permitted.)
• •Radiographic or clinical evidence of progressive disease.
• •Negative HRD result in a previous pre-screening in this trial.
• •\[...\]
• •Patients with symptomatic uncontrolled central nervous system (CNS) metastases.
• •Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days.
• •History of leptomeningeal carcinomatosis.
• •Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy. Exceptions are:
• •1. Alopecia (any Grade)
• •2. Vitiligo (any Grade)
• •3. Hypothyroidism stable on hormone replacement (Grade ≤2)
• •4. Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician
• •5. Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or olaparib may be included only after consultation with the Sponsor.
• •6. ...